Can Donors With Prior Hepatitis Be Safely Used for Heart Transplantation?

Journal of Heart and Lung Transplantation

Volumn 25, Issue 7, 2006, Pages 805-813

  Mawhorter, Steven D ^a   Avery, Robin K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ADEFOVIR; ALPHA INTERFERON; FAMCICLOVIR; HEPATITIS B ANTIBODY; IMMUNOGLOBULIN; LAMIVUDINE; RIBAVIRIN; TENOFOVIR; VIRUS DNA; VIRUS RNA;

DONOR SELECTION; HEART TRANSPLANTATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; MEDICAL LITERATURE; MEDLINE; NUCLEIC ACID ANALYSIS; ORGAN DONOR; PRIORITY JOURNAL; RECIPIENT; REVIEW; RISK ASSESSMENT; SCREENING TEST; SEROLOGY; VACCINATION; VIRUS TRANSMISSION;

HEART TRANSPLANTATION; HEPATITIS B; HEPATITIS C; HUMANS; MEDICAL RECORDS; RISK; TISSUE DONORS;

EID: 33745487372     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2006.03.002     Document Type: Review

References (61)

1. Rosengard B.R., Feng S., Alfrey E.J., et al. Report of the Crystal City meeting to maximize the use of donor organs recovered from the cadaver donor. Am J Transplant 2 (2002) 701-711
2. http://www.osotc.org/st_wait.htm. Accessed Sept 29, 2004.
3. Xu D.Z., Yan Y.P., Choi B.C., et al. Risk factors and mechanism of transplacental transmission of hepatitis B virus. a case-control study. J Med Virol 67 (2002) 20-26
4. Agnello V., and Abel G. Localization of hepatitis C virus in cutaneous vasculitic lesions in patients with type II cryoglobulinemia. Arthritis Rheum 40 (1997) 2007-2015
5. Chung R.T., Feng S., and Delmonico F.L. Approach to the management of allograft recipients following the detection of hepatitis B virus in the prospective organ donor. Am J Transplant 1 (2001) 185-191
6. Delmonico F.L. Cadaver donor screening for infectious agents in solid organ transplantation. Clin Infect Dis 31 (2000) 781-786
7. Lok A.S., Lai C.L., and Wu P.C. Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection. implications in hepatitis B vaccination programs. Hepatology 8 (1988) 766-770
8. Turner D.P., Zuckerman M., Alexander G.J., Waite J., and Wreghitt T. Risk of inappropriate exclusion of organ donors by introduction of hepatitis B core antibody testing. Transplantation 63 (1997) 755-777
9. Meng Q., Wong C., Rangachari A., et al. Automated multiplex assay system for simultaneous detection of hepatitis B virus DNA, hepatitis C virus RNA, and human immunodeficiency virus type I RNA. J Clin Microbiol 39 (2001) 2937-2945
10. Ko W.J., Chou N.K., and Hsu R.B. Hepatitis B virus infection in heart transplant recipients in a hepatitis B endemic area. J Heart Lung Transplant 20 (2001) 865-875
11. Natov S.N., and Pereira B.J. Transmission of viral hepatitis by kidney transplantation. donor evaluation and transplant policies. Transplant Infect Dis 4 (2002) 117-123
12. McMahon B.J., Parkinson A.J., Helminiak C., et al. Response to hepatitis B vaccine of persons positive for antibody to hepatitis B core antigen. Gastroenterology 103 (1992) 590-594
13. Wachs M.E., Amend W.J., Ascher N.L., et al. The risk of transmission of hepatitis B from HBsAg (-), HBcAb (+), HBIgM (-) organ donors. Transplantation 59 (1995) 230-234
14. Madayag R.M., Johnson L.B., Bartlett S.T., et al. Use of renal allografts from donors positive for hepatitis B core antibody confers minimal risk for subsequent development of clinical hepatitis B virus disease. Transplantation 64 (1997) 1781-1786
15. Satterthwaite R., Ozgu I., Shidban H., et al. Risks of transplanting kidneys from hepatitis B surface antigen-negative, hepatitis B core antibody-positive donors. Transplantation 64 (1997) 432-435
16. Pinney S.P., Cheema F.H., Hammond K., et al. Acceptable recipient outcomes with the use of hearts from donors with hepatitis B core antibodies. J Heart Lung Transplant 24 (2005) 34-37
17. Noborg U., Gusdal A., Horal P., and Lindh M. Levels of viremia in subjects with serological markers of past or chronic hepatitis B virus infection. Scand J Infect Dis 32 (2000) 249-252
18. Hennig H., Puchta I., Luhm J., et al. Frequency and load of hepatitis B virus DNA in first-time blood donors with antibodies to hepatitis B core antigen. Blood 100 (2002) 2637-2641
19. Van Thiel D.H., De Maria N., Alessandra C., and Friedlander L. Can hepatits B core antibody positive livers be used safely for transplantation?. Hepatitis B virus detection in the liver of individuals who are hepatitis B core antibody positive. Transplantation 68 (1999) 519-522
20. Kuhns M.C., Kleinman S.H., McNamara A.L., et al. Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc. implications for future HBV screening policy. Transfusion 44 (2004) 1332-1339
21. Douglas D.R.J., Marnish D., Wright T., Krom R., and Wiesner R. Transmission of hepatitis B virus infection from orthotopic donor livers. Hepatology 16 (1992) 49A
22. Avery R.K., and Ljungman P. Prophylactic measures in the solid-organ recipient before transplantation. Clin Infect Dis 33 suppl 1 (2001) S15-S21
23. Chazouilleres O., Marnish D., Kim M., et al. Hepatitis B virus as source of infection in liver transplant recipients. Lancet 343 (1994) 142-146
24. Fagiuoli S., Minniti F., and Pevere S. HBV and HCV infections in heart transplant recipients. J Heart Lung Transplant 20 (2001) 718-724
25. Turik M.A., and Markowitz S.M. A successful regimen for the prevention of seroconversion after transplantation of a heart positive for hepatitis B surface antigen. J Heart Lung Transplant 11 (1992) 781-783
26. Lunel F., Cadranel J.F., Rosenheim M., et al. Hepatitis virus infections in heart transplant recipients. epidemiology, natural history, characteristics, and impact on survival. Gastroenterology 119 (2000) 1064-1074
27. Wedemeyer H., Pethid K., Wagner D., et al. Long-term outcome of chronic hepatitis B in heart transplant recipients. Transplantation 66 (1998) 1347-5
28. Hosenpud J.D., Pamidi S.R., and Fiol B.S. Outcomes in patients who are hepatitis B surface antigen-positive before transplantation. an analysis and study using the joint ISHLT/UNOS thoracic registry. J Heart Lung Transplant 19 (2000) 781-785
29. Zheng S.S., Wu J., Liang T.B., et al. Prophylaxis and treatment of hepatitis B virus reinfection following liver transplantation. Hepatobil Pancreat Dis Int 1 (2002) 327-329
30. Benhamou Y., Tubiana R., and Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med 348 (2003) 177-178
31. Perrillo R., Schiff E., Yoshida E., et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 32 (2000) 129-134
32. Toniutto P., Fumo E., Caldato M., et al. Favorable outcome of adefovir-dipivoxil treatment in acute de novo hepatitis B after liver transplantation. Transplantation 77 (2004) 472-473
33. Avery R.K. Prevention and treatment of cytomegalovirus infection and disease in heart transplant recipients. Curr Opin Cardiol 13 (1998) 122-129
34. Wedemeyer H., Boker K.H., and Pethig K. Famciclovir treatment of chronic hepatitis B in heart transplant recipients. a prospective trial. Transplantation 68 (1999) 1503-1511
35. Lo C.M., Cheung S.T., Ng I.O., et al. Fibrosing cholestatic hepatitis secondary to precore/core promoter hepatitis B variant with lamivudine resistance. successful retransplantation with combination adefovir dipivoxil and hepatitis B immunoglobulin. Liver Transplant 10 (2004) 557-563
36. Papatheodoridis G.V., Sevastianos V., and Burroughs A.K. Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. Am J Transplant 3 (2003) 250-258
37. Mawhorter S, Nasrallah M, Starling R, et al. Assessment of an accelerated hepatitis B vaccination protocol in congestive heart failure and left-ventricular assist device patients awaiting heart transplantation. Am J Transplant 2003(suppl 5):528.
38. Joya-Vazquez P.P., Dodson F.S., Dvorchik I., et al. Impact of anti-hepatitis Bc-positive grafts on the outcome of liver transplantation for HBV-related cirrhosis. Transplantation 73 (2002) 1598-1602
39. Lopez-Navidad A., and Caballero F. Extended criteria for organ acceptance. Strategies for achieving organ safety and for increasing organ pool. Clin Transplant 17 (2003) 308-324
40. Pol S., Legendre C., Mattlinger B., Berthelot P., and Kreis H. Genetic basis of nonresponse to hepatitis B vaccine in hemodialyzed patients. J Hepatol 11 (1990) 385-387
41. Arbustini E., Dal Bello B., and Morbini P. Factors increasing the risk of allograft vascular disease in heart transplant recipients. G Ital Cardiol 27 (1997) 985-999
42. Kalayoglu M.R., Libby P., and Byrne G.I. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA 288 (2002) 2724-2731
43. Mawhorter S.D., and Lauer M.A. Is atherosclerosis an infectious disease?. Cleve Clin J Med 68 (2001) 449-458
44. Valantine H.A., Gao S.Z., Menon S.G., et al. Impact of prophylactic immediate post transplant ganciclovir on development of transplant atherosclerosis. Circulation 100 (1999) 61-66
45. Haji S.A., Tuzcu E.M., Starling R.C., et al. Donor or recipient hepatitis B infection accelerates allograft vasculopathy. Am J Transplant 2 (2002) 247
46. Marelli D., Bresson J., and Laks H. Hepatitis C-positive donors in heart transplantation. Am J Transplant 2 (2002) 443-447
47. Ong J.P., Barnes D.S., Younossi Z.M., et al. Outcome of de novo hepatitis C virus infection in heart transplant recipients. Hepatology 30 (1999) 1293-1298
48. Pereira B.J., Milford E.L., and Kirkman R.L. Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody and in the recipients of their organs. N Engl J Med 327 (1992) 910-915
49. Gordon S.M., Carey W., Yen-Lieberman B., et al. A fatal case of hepatitis C seroconversion following living-related kidney transplantation. another argument for nucleic acid amplification testing of transplant recipients and donors. Transplant Infect Dis 4 (2002) 113-114
50. Pfau P.R., Rho R., and DeNofrio D. Hepatitis C transmission and infection by orthotopic heart transplantation. J Heart Lung Transplant 19 (2000) 350-354
51. Minami K., and Koefer R. Outcome of heart transplantation in patients previously infected with hepatitis C virus. J Heart Lung Transplant 20 (2001) 595-598
52. Tugwell B.D., Patel P.R., Williams I.T., et al. Transmission of hepatitis C virus to several organ and tissue recipients from an antibody-negative donor. Ann Intern Med 143 (2005) 648-654
53. Fagiuoli S., Cooper D.K., and Zuhdi N. Hepatitis C status of heart transplant recipients. Clin Transplant 12 (1998) 5-10
54. Chan S.E., Schwartz J.M., and Rosen H.R. Treatment of hepatitis C in solid organ transplantation. Drugs 64 (2004) 489-498
55. Pereira B.J. Hepatitis C in organ transplantation. its significance and influence on transplantation policies. Curr Opin Nephrol Hypertens 2 (1993) 912-922
56. Dal Bello B., Klersy C., and Grossi P. Combined human cytomegalovirus and hepatitis C virus infections increase the risk of allograft vascular disease in heart transplant recipients. Transplant Proc 30 (1998) 2086-2090
57. Haji S.A., Starling R.C., Avery R.A., et al. Donor hepatitis C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation. J Heart Lung Transplant 23 (2004) 277-283
58. Lake K., Aaronson K., Naftel D., et al. Outcomes with hepatitis C following cardiac transplantation. 10 year follow-up. J Heart Lung Transplant 24 suppl 2S (2005) S77
59. Fagiuoli S., Pevere S., and Livi U. Lymphoproliferative disorders in heart transplant recipients. role of hepatitis C virus (HCV) and Epstein-Barr virus (EBV) infection. Transplant Int 13 suppl 1 (2000) S402-S405
60. Lake K.D., Smith C.I., LaForest S.K., et al. Policies regarding the transplantation of hepatitis C-positive candidates and donor organs. J Heart Lung Transplant 16 (1997) 917-921
61. Barcena Marugan R., Garcia-Hoz F., Vazquez Romero M., et al. Prevention of de novo hepatitis B infection in liver allograft recipients with previous hepatitis B infection or hepatitis B vaccination. Am J Gastroenterol 97 (2002) 2398-2401